SUTRO BIOPHARMA, INC. Pre-Tax Income
SUTRO BIOPHARMA, INC. (STRO) reported Pre-Tax Income of -$38.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$38.53M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$38.50M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$46.84M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$56.86M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$191.18M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$225.10M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$88.60M.
- SUTRO BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$116.70M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$38.53M 10-Q · filed 2026-08-12 | -$77.03M 10-Q · filed 2026-08-12 | -$123.88M derived: sum of 3 quarters · filed 2026-08-12 | -$180.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$38.50M 10-Q · filed 2026-05-14 | -$85.34M derived: sum of 2 quarters · filed 2026-05-14 | -$142.20M derived: sum of 3 quarters · filed 2026-05-14 | -$153.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$46.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$103.70M derived: sum of 2 quarters · filed 2026-03-23 | -$115.22M derived: sum of 3 quarters · filed 2026-08-12 | -$191.18M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$56.86M 10-Q · filed 2025-11-06 | -$68.37M derived: sum of 2 quarters · filed 2026-08-12 | -$144.34M 10-Q · filed 2025-11-06 | -$214.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$11.52M 10-Q · filed 2026-08-12 | -$87.48M 10-Q · filed 2026-08-12 | -$157.57M derived: sum of 3 quarters · filed 2026-08-12 | -$206.35M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$75.96M 10-Q · filed 2026-05-14 | -$146.05M derived: sum of 2 quarters · filed 2026-05-14 | -$194.84M derived: sum of 3 quarters · filed 2026-05-14 | -$242.85M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$70.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$118.88M derived: sum of 2 quarters · filed 2026-03-23 | -$166.88M derived: sum of 3 quarters · filed 2026-03-23 | -$225.10M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$48.79M 10-Q · filed 2025-11-06 | -$96.80M derived: sum of 2 quarters · filed 2025-11-06 | -$155.01M 10-Q · filed 2025-11-06 | -$108.14M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$48.01M 10-Q · filed 2025-08-07 | -$106.22M 10-Q · filed 2025-08-07 | -$59.35M derived: sum of 3 quarters · filed 2025-08-07 | -$106.80M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$58.21M 10-Q · filed 2024-05-13 | -$11.34M derived: sum of 2 quarters · filed 2025-03-13 | -$58.79M derived: sum of 3 quarters · filed 2025-03-13 | -$97.16M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | $46.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$573.00K derived: sum of 2 quarters · filed 2025-03-13 | -$38.95M derived: sum of 3 quarters · filed 2025-03-13 | -$88.60M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$47.45M 10-Q · filed 2024-11-13 | -$85.82M derived: sum of 2 quarters · filed 2024-11-13 | -$135.47M 10-Q · filed 2024-11-13 | -$170.07M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$38.37M 10-Q · filed 2024-08-13 | -$88.03M 10-Q · filed 2024-08-13 | -$122.62M derived: sum of 3 quarters · filed 2025-03-13 | -$142.11M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$49.66M 10-Q · filed 2024-05-13 | -$84.25M derived: sum of 2 quarters · filed 2025-03-13 | -$103.74M derived: sum of 3 quarters · filed 2025-03-13 | -$127.25M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$34.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$54.08M derived: sum of 2 quarters · filed 2025-03-13 | -$77.59M derived: sum of 3 quarters · filed 2025-03-13 | -$116.70M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$19.49M 10-Q · filed 2023-11-13 | -$43.00M derived: sum of 2 quarters · filed 2023-11-13 | -$82.11M 10-Q · filed 2023-11-13 | -$120.23M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | -$23.51M 10-Q · filed 2023-08-10 | -$62.62M 10-Q · filed 2023-08-10 | -$100.75M derived: sum of 3 quarters · filed 2024-03-25 | -$131.65M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$39.11M 10-Q · filed 2023-05-15 | -$77.23M derived: sum of 2 quarters · filed 2024-03-25 | -$108.14M derived: sum of 3 quarters · filed 2024-03-25 | -$114.29M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | -$38.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$69.03M derived: sum of 2 quarters · filed 2024-03-25 | -$75.18M derived: sum of 3 quarters · filed 2024-03-25 | -$105.54M 10-K · filed 2024-03-25 |
| 2021-09-30 | -$30.90M 10-Q · filed 2022-11-08 | -$37.05M derived: sum of 2 quarters · filed 2022-11-08 | -$67.41M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$6.15M 10-Q · filed 2022-08-08 | -$36.51M 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | -$32.02M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |